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Abstract
The cytokine micro-environment can direct murine CD4+ T cells towards various differentiation lineages such as Th1, Th2
and Tregs even in the presence of rapamycin, which results in T cells that mediate increased in vivo effects. Recently, a new
lineage of T cells known as Th9 cells that secrete increased IL-9 have been described. However, it is not known whether Th9
differentiation occurs in the presence of rapamycin or whether adoptively transferred donor Th9 cells would augment or
restrict alloreactivity after experimental bone marrow transplantation. We found that CD4+ T cells that were co-stimulated
and polarized with TGF-b and IL-4 in the presence or absence of rapamycin each yielded effector cells of Th9 phenotype
that secreted increased IL-9 and expressed a transcription factor profile characteristic of both Th9 and Th2 cells (high GATA-
3/low T-bet). Augmentation of T cell replete allografts with manufactured rapamycin resistant Th9 cells markedly reduced
both CD4+ and CD8+ T cell engraftment and strongly inhibited allo-specific T cell secretion of IFN-c. The potency of Th9 cell
inhibition of alloreactivity was similar to that of rapamycin resistant Th2 cells. Importantly, rapamycin resistant Th9 cells
persisted and maintained their cytokine phenotype, thereby indicating limited differentiation plasticity of the Th9 subset. As
such, Th9 differentiation proceeds in the presence of rapamycin to generate a cell therapy product that maintains high IL-9
expression in vivo while inhibiting IFN-c driven alloreactivity.
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Introduction
CD4+ T helper subsets can differentiate into various lineages in
response to environmental cues such as cytokines or ligand
interactions. Of the various lineages of T helper subsets, Th9 cells
are a recent addition. Th9 cells develop from CD4 precursors in
response to TGF-b and IL-4 and are primarily characterized by
their increased secretion of IL-9 [1]. While IL-9 producing CD4+
T cells were previously classified as Th2 cells [2], recent studies
have shown that Th9 cells are a distinct lineage of T helper cells
[1,3]. Th9 cells have been implicated in various disease processes
that have been associated with Th2 cells, including: helminth
infection [4] [1], allergy [5] and asthma [6] [7]. However, Th9
cells can share mechanistic features of Th1 cells, as they have been
associated with solid organ graft rejection [8], experimental
peripheral neuritis [3] and anti-tumor responses [9]. On the other
hand, the tolerogenic properties of Th9 cells were noted in a
transplantation setting where IL-9 promoted allograft tolerance
[10]. As such, there are somewhat conflicting data with respect to
the role of Th9 cells in immunity, and no data exists concerning
their potential role after experimental allogeneic bone marrow
transplantation.
Rapamycin is an immunosuppressive drug that blocks cell
surface signaling through inhibition of the kinase, mammalian
target of rapamycin (mTOR) [11]. Although rapamycin can
preferentially expand regulatory T cells (Tregs) [12] [13] in some
models, we have shown that polarization towards Type I and Type
II CD4+ T cells [14] [15,16,17] can be achieved in the presence of
rapamycin provided that APC free co-stimulation is administered
along with sufficient polarizing cytokines. In murine transplant
models [17,18] and in a human-into-mouse xenogeneic transplant
model [15], we have shown that such rapamycin resistant effector
T cell subsets possess an anti-apoptotic phenotype [19], persist
in vivo after adoptive transfer, have stability of the defined
cytokine phenotype and mediate increased transplantation effects.
A phase II clinical trial of rapamycin resistant T cells has been
completed [20].
Given the apparent role of Th9 cells in mediating anti-tumor
effects [9] while limiting inflammation [10], and the potential
beneficial role of ex vivo rapamycin for cell therapy efforts [21], we
initiated an effort to determine whether: (1) it might be possible to
achieve Th9 polarization in the presence of rapamycin; (2) such
rapamycin resistant Th9 cells might maintain their cytokine
phenotype in vivo; and (3) in the context of a T cell replete model
of experimental bone marrow transplantation, allograft augmen-




BALB/c (H-2Kd), C57BL/6 (H-2Kb) and Ly5.1 congenic (H-
2Kb) mice were obtained from Frederick Cancer Research facility
(Frederick, MD). All mice were 6–8 weeks old, maintained in a
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specific pathogen-free facility at the National Institutes of Health.
Experiments were performed in accordance with the guidelines of
the NIH Animal Care and Use Committee (ACUC). The protocol
was approved by the NCI ACUC (protocol number MB-075).
In vitro Generation of Rapamycin-resistant Th9 Cells
Spleen cells from C57BL/6 mice were harvested and lysed
using ACK lysing buffer (Quality Biological, Inc., Gaithersburg,
MD). B cells were depleted using goat-anti-mouse conjugated
magnetic bioparticles (Polysciences Inc., Warrington, PA). To
generate CD3, CD28 mAb coated beads; M450 Dynabeads
(Dynal ASA, Oslo, Norway) were incubated with anti-murine
CD3 and CD28 mAbs (BD Pharmingen, San Diego, CA) in 0.1M-
borate solution at 37uC overnight. CD3, CD28 mAb coated beads
were then washed with PBS containing 3% FBS (Gemini Bio-
Products, Woodland, CA), 5mM EDTA (Quality Biological, Inc.)
and 0.1% sodium azide (Sigma, St. Louis, MO), and brought up in
the same solution at a concentration of 406106 beads/ml. Control
rapamycin resistant Th1 cells (Th1.R) were generated using
aCD3/aCD28-coated beads in RPMI complete media with
20 IU/mL rhIL-2, 20 ng/mL rhIL-7, 20 ng/ml rmIL-12 (Pepro-
tech), 10 mM of Rapamycin (LC Laboratories, Woburn, MA) and
3.3 mM NAC. Control rapamycin resistant Th2 cells (Th2.R)
were cultured exactly the same except for the addition of
1000 IU/ml of rm IL-4 instead of rmIL-12. Culture conditions
for the manufacture of Th9 cells were exactly the same as for Th2
cells except for the further addition of 5 ng/ml rhTGF-b1.
Specific cytokine-containing complete media was added to all
cultures daily from days 2–6 to maintain a cell concentration
between 0.2–1.06106 cells/mL. After 6 days in culture, the
various T helper cell subsets were used for bone marrow transplant
experiments, multiplex bead array, and flow cytometry analysis.
Cytokine Secretion Assays
Rapamycin-generated Th2 (Th2.R) and Th9 (Th9.R) cells were
harvested (day 6) and adjusted to 16106 cells/ml in 24-well plates
with or without aCD3/aCD28 beads. Twenty-four-hour culture
supernatants were collected; cytokine content was evaluated by
Bio-Plex multiplex sandwich immunoassay (Bio-Rad).
Bone Marrow Transplantation
Host BALB/c (H-2Kd) mice were lethally irradiated (950cGy;
137Cs g-radiation source; Gamma Cell 40; Atomic Energy of
Canada, Ottawa, Canada) and reconstituted with parental B6 (H-
2Kb) bone marrow cells (56106 cells) and pan T cells (16106 cells)
intravenously (i.v.). Some cohorts received in vitro cultured Th2.R
(106106 cells) or Th9.R (106106 cells) cells. In vivo alloreactivity
was allowed to occur and immune biology was studied at day 14
post-transplant.
Flow Cytometry Analysis of T Cells
Splenocytes from BALB/c mice were obtained at day 14 post-
BMT. Day 14 splenocytes were stained with CD4 PE-cy5
(H129.19), H2K
b PE (AF6.88.5), CD3 FITC (145-2C11),
CD45.1 APC (A20) and CD45.2 PE-cy7 (104). For intracellular
cytokine measurement, T cells were stimulated for 4h with
phorbol 12-myristate 13-acetate and ionomycin (Sigma) followed
by the addition of Brefeldin A (GolgiPlug) and Monensin (Golgi
stop) for the last 2hrs. Cells were then fixed, permeabilized and
stained to detect IFN-c FITC (XMG1.2), IL-9 PE (RM9A4) and
IL-4 APC (11B11). All antibody staining was performed in the
presence of aCD16/32 (9.3; eBioscience). Cells were then
analyzed using LSRII and FlowJo software. All antibodies were
obtained from BD Bioscience unless otherwise stated.
In Vivo Tracking of Donor Th2.R and Th9.R Populations
and Unmanipulated CD4 and CD8 T Cells
To allow cell tracking, Th2.R and Th9.R cells were generated
using splenic T cells from CD45.1 C57BL/6 congenic mice. Anti-
CD45.2 PE.cy7(BD Pharmingen) was used to track unmanipulat-
ed CD4 and CD8 populations.
Determination of in vivo Allosensitization
Spleen cells collected post-BMT were subjected to: no
stimulation, aCD3/aCD28 stimulation, B6 syngeneic DC stimu-
lation or BALB/c allogeneic DC stimulation. For aCD3/aCD28
stimulation, spleen cells were adjusted to a concentration of
0.56106 cells/ml and incubated with CD3/CD28 beads. DCs
were obtained by culturing marrow cells for 4 days in rmGM-CSF
and rmIL-4 (each at 1000 IU/ml; PeproTech); bacterial LPS
(1 mg/ml; Calbiochem) was added to final 24 h of DC culture.
Expanded DC were washed and used at a ratio of 10:1 (spleen
cell:DC). For cytokine analysis, twenty-four-hour culture superna-
tants were collected; cytokine content (IL-4, IL-9, IFN-c and TNF-
a) was evaluated by Bio-Plex multiplex sandwich immunoassay
(Bio-Rad).
Statistics
Statistical analysis was determined using GraphPad Prism 4
software. P values from data presented as histograms, unless stated
otherwise, were determined using a two-tailed unpaired t test.
Unless stated otherwise, histogram columns represent the mean
values for each experiment and error bars indicate the standard
error of mean. Single asterisk (*) denotes P,0.05, double asterisk
(**) denotes P,0.01, and triple asterisk (***) denotes P,0.001.
Results
Th9 Polarization Occurs in the Presence of Rapamycin
Using intra-cellular cytokine flow cytometry, we found that bulk
CD4+ T cells were capable of being polarized into Th1, Th2 or
Th9 cells in the presence or absence of rapamycin (Representative
data; Figure 1a). The frequency of IFN-c secreting cells was
reduced in each subset by rapamycin, with the Th2 and Th9
subsets being lower than the Th1 subset (Figure 1b). Both Th9 and
Th9.R cultures had an increased frequency of IL-9 secreting cells
relative to the other subsets (Figure 1c). Using transcription factor
I.C. flow cytometry, we found that T-bet was highly expressed by
Th1 and Th1.R cells (Figure 1d and 1e) whereas both Th2/Th2.R
and Th9/Th9.R cells preferentially expressed GATA3 (Figure 1d
and 1f).
Murine Th9 Cells Expanded in Rapamycin Secrete IL-9
in vitro
Using multiplex bead array system, the cytokine secretion
profile of Th2.R and Th9.R was tested. Th2.R and Th9.R
secreted low levels of IL-2 and IFN-c (Figure 2a) and similar
magnitudes of IL-4 and IL-9 (Figure 2a). The ratio of IL-4 to IL-9
tended to be higher in the Th2.R subset but this difference did not
reach statistical significance (Figure 2b); similarly, the ratio of IL-9
to IL-4 tended to be higher in the Th9.R subset but did not reach
statistical significance (Figure 2c).
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Murine Th9.R Cells Inhibit IFN-c Mediated GVHR
Murine recipients were reconstituted with BM and allogeneic T
cells following TBI. Certain cohorts received additional Th2.R or
Th9.R cells that were expanded from CD45.1 C57BL6 donors. At
day 14, splenocytes from cohorts that were treated with Th2.R or
Th9.R cells secreted reduced IFN-c and TNF-a in response to
allogeneic DC stimulation (Figure 3a, 3b). Co-transfer of Th9.R
cells, but not Th2.R cells, resulted in decreased engraftment of
donor CD8+ T cells (Figure 3c). However, both Th9.R and Th2.R
cells reduced the frequency of IFN-c producing donor CD8+ T
cells (Figure 3d). By comparison, Th2.R cells but not Th9.R cells
increased the number of post-transplant donor CD4+ T cells that
were derived from the unmanipulated T cell inoculum
(CD45.2+)(Figure 3e). Both Th9.R and Th2.R cells reduced the
frequency of IFN-c producing donor CD45.2+CD4+ T cells
(Figure 3f). At day 14 post-BMT, the adoptively transferred Th2.R
and Th9.R populations were present in vivo at similar levels
(absolute number of Th2.R vs. Th9.R cells, 6106 per spleen;
Mean 6 SEM: 9.361.9 vs. 761.7). Similar to their phenotype at
the time of adoptive cell transfer, Th9.R and Th2.R cells
harvested at day 14 post- BMT preferentially produced either
IL-9 or IL-4, respectively (Figure 3g).
Figure 1. Th9 polarization proceeds in the presence of rapamycin. Splenocytes were harvested from C57B6 mice and bulk CD4+ T cells were
isolated. CD4+ T cells were polarized to either Th1 or Th2 or Th9 differentiation for 6 days. At day 6, cells were washed and characterized for cytokine
production and transcription factor expression by I.C. flow cytometry. (A) Representative dot plot showing IL-9 versus IFN-c production in Th1 cells,
Th1 cells grown in rapamycin (Th1.R), Th2 cells, Th2.R, Th9 cells and Th9.R cells. (B) Summary of three independent experiments showing IFN-
cproduction in the various CD4+ T helper subsets. (C) Summary of three independent experiments showing IL-9 production in the various CD4+ T
helper subsets. (D) Representative dot plot showing T-bet versus GATA3 expression in Th1 cells, Th1.R cells, Th2 cells, Th2.R, Th9 cells and Th9.R cells.
(E) Summary of three independent experiments showing T-bet expression in the various CD4+ T helper subsets. (F) Summary of three independent
experiments showing GATA3 expression in the various CD4+ T helper subsets. Single asterisk (*) denotes P,0.05, double asterisk (**) denotes P,0.01,
and triple asterisk (***) denotes P,0.001.
doi:10.1371/journal.pone.0072305.g001
Figure 2. Cytokine Profile of CD4+ Th9.R cells. Splenocytes were harvested from C57B6 mice and bulk CD4+ T cells were isolated. CD4+ T cells
were polarized to either Th1 or Th2 or Th9 differentiation for 6 days. At day 6, cells were washed and characterized for cytokine production by
Multiplex Luminex assay. (A) Shows Th1/Th2 cytokine secretion profile of Th2 and Th9 cells expanded in the presence of rapamycin. (B) Ratio of IL-4
versus IL-9 cytokine production in Th2.R and Th9.R cells, (C) Ratio of IL-9 versus IL-4 cytokine production in Th2.R and Th9.R cells.
doi:10.1371/journal.pone.0072305.g002
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Figure 3. Rapamycin resistant Th9 cells inhibit alloreactivity in vivo. Host BALB/c mice were subjected to TBI (950cGY) and then
reconstituted with allogeneic CD45.2 B6 BM (10M) and T cells (1M). In certain cohorts, mice received either Th2.R or Th9.R cells (10M) that were
generated from congeneic CD45.1 mice. At day 14, splenocytes were harvested and restimulated with either syngeneic or allogeneic DC. (A)
Alloreactive IFN-c secretion in the different cohorts. (B) Alloreactive TNF-a secretion. (C) Absolute numbers of donor CD45.2+ CD8+ T cell engraftment
in the various cohorts at day 14 post-BMT. (D) Absolute numbers of post-BMT donor CD8+ T cells that produce IFN-c after PMA/ionomycin stimulation
was detected by I.C. flow cytometry. (E) Absolute number of donor CD45.2+ CD4+ T cell engraftment in the various cohorts at day 14 post-BMT. (F)
Absolute numbers of post-BMT donor CD45.2+ CD4+ T cells that produce IFN-c after PMA/ionomycin stimulation. (G) Ex vivo cytokine production of
Rapamycin Resistant Th9 Cells Inhibit Alloreaction
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Discussion
In this study, we have initiated an evaluation of the in vitro
phenotype and in vivo stability of rapamycin resistant Th9 cells
during graft-versus-host-reactivity. The data presented here shows
that Th9 cells: (1) can be polarized in the presence of rapamycin,
(2) possess cytokine phenotype stability in vivo during allogeneic
BMT; and (3) inhibit IFN-c mediated graft-versus-host-reactivity.
The data presented here are the first to demonstrate that Th9
cell differentiation can proceed in the presence of rapamycin. The
current finding extends previous observations on the relatively
unbiased nature of CD4+ T cell differentiation in rapamycin [21].
The results presented here further confirm that the effect of
rapamycin in blocking CD4+ T cell differentiation [12] can be
overcome by using an APC free system along with polyclonal
stimulation and adequate cytokine availability. Such expanded
Th9.R cells were similar in cytokine phenotype and transcription
factor profile to their non-rapa counterparts (Th9 cells). Also, in
keeping with previous reports on Th9 cells [8] [2], we found that
Th9.R cells were similar to Th2.R cells in terms of transcription
factor expression and cytokine profile.
For the first time, we have demonstrated the phenotype stability
of Th9.R cells in vivo during allogeneic BMT. Differentiation
plasticity of T helper subsets during allogeneic BMT [22] [23]
raises concerns with respect to the use of T helper cell therapy.
Also, previous reports have suggested that Th9 cells are only
transient IL-9 producers [24] and are prone to plasticity [25]
in vivo during inflammation. In this context, it is noteworthy that
we found that Th9.R cells inhibited type I cytokine production of
allo-reactive T cells while maintaining their IL-9 producing
capacity. Moreover, lineage stability was not exclusive to Th9.R
cells but was also observed with respect to Th2.R cells. Taken
together, these results indicate that expansion of T helper subsets
in rapamycin may render lineage stability in vivo during
inflammation, thereby enhancing the fidelity of defined T helper
cell therapy.
This report is also the first to demonstrate an immune
modulation function of Th9.R cell function during experimental
allogeneic BMT. Specifically, we found that Th9.R cells inhibited
IFN-c driven alloreactivity with a potency similar to Th2.R cells.
This finding indicates that it is possible to deliver cells with
increased IL-9 secretion capacity without exacerbating alloreac-
tivity. Further studies will be required to determine whether
transfer of T cells with increased IL-9 secretion capacity do not
increase GVHD or whether such cells might improve graft-versus-
tumor-effects.
One might argue as others have previously asserted [2], that
because the Th2.R and Th9.R cells had a similar in vitro
phenotype and mediated similar in vivo inhibition of alloreactiv-
ity, these subsets are essentially the same T cell product and
without substantial differential effect. However, contrary to this
line of reasoning, we found that the Th2.R and Th9.R products
had highly differential effects on donor T cell engraftment.
Namely, donor Th9.R cells greatly inhibited donor CD8
engraftment during allogeneic BMT; Th2.R cells, on the other
hand, did not inhibit donor CD8+ T cell engraftment. It is possible
that the potent ability of Th9.R cells to limit CD8+ T cell
engraftment may offer an improved balance to GVHD and GVT
effects [9]. Similarly marked differential effects were also observed
in terms of donor CD4+ T cell engraftment; that is, whereas
Th2.R cell infusion increased donor CD4+ T cell engraftment,
Th9.R cell infusion did not increase donor CD4+ T cell numbers
post- BMT. Thus relative to the Th2.R population, Th9.R cells
were equally efficient in terms of inhibiting IFN-c driven
alloreactivity and more potent in terms of limiting donor CD4+
and CD8+ T cell numbers post-BMT. Further studies are therefore
warranted to determine the differential effects of Th2.R and
Th9.R cell therapy in the modulation of transplant responses after
allogeneic bone marrow transplantation.
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